Fox Chase Cancer Center News

PHILADELPHIA (July 20, 2021)—Delinda Pendleton, BSN, MSN, a long-time employee at Fox Chase Cancer Center, has been named a Planetree Fellow in Person-Centered Care. The fellows program is operated by Planetree International, a leading person-centered care advocacy and standard setting organization.

PHILADELPHIA (July 13, 2021)—Researchers at Fox Chase Cancer Center have recently shown that sonic hedgehog-driven (SHH) medulloblastoma relapse may be prevented by targeting the transdifferentiation—a cell’s ability to convert from one type of cell to another—of astrocytes.

PHILADELPHIA (July 13, 2021)—Researchers at Fox Chase Cancer Center have received a grant to study how stem cells in the ovary respond to nutrition, particularly in ways that mirror certain cancers.

PHILADELPHIA (July 13, 2021)– Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Fox Chase Cancer Center in Philadelphia, PA, has been added as an active trial site for the dose-expansion stage of the ongoing clinical trial evaluating the company’s lead drug candidate, seclidemstat, in patients with relapsed or refractory Ewing sarcoma and advanced FET-rearranged sarcomas.

PHILADELPHIA (July 8, 2021) — The white blood cells called T-cells play a critical role in immune function. However, for many years, scientists didn’t know why these cells divided into so-called CD8 “killer” T-cells, which fight and destroy pathogens, and CD4 “helper” T-cells, which play a supporting role by triggering the body’s wider immune response.

PHILADELPHIA (July 8, 2021) — Survivors of head and neck cancers might benefit from an interdisciplinary survivorship clinic that includes assessment and screening by rehabilitation specialists, according to Fox Chase Cancer Center researchers.

PHILADELPHIA (July 8, 2021) — Mechanical removal is safer than more traditional methods of burning or ablating tumors that arise from recurrent respiratory papillomatosis (RRP), a respiratory disease caused by the human papilloma virus, according to the findings of a case series published recently by researchers at Fox Chase Cancer Center.

PHILADELPHIA (July 7, 2021) - Sanjeevani Arora, PhD, assistant professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center, has received the Yale Head and Neck Specialized Program of Research Excellence (SPORE) Career Enhancement Program (CEP) Award. Arora will receive a one-year grant of $50,000 and eligibility for a second year of funding.